Ramipril

Ramipril is among the most widely prescribed antihypertensive medications in the UK, recommended across multiple NICE guidelines for hypertension treatment, heart failure management, and cardiovascular protection. Ramipril tablets are a prescription-only ACE inhibitor used in adults for several cardiovascular conditions. As part of cardiovascular therapy, ramipril acts on the renin-angiotensin system to lower blood pressure and reduce the risk of serious cardiovascular events. A prescription can only be issued following a clinical consultation.

Ramipril tablets are an oral prescription medicine containing ramipril as the active ingredient. Ramipril belongs to the ACE inhibitor class of medicines, which act on the renin-angiotensin system to lower blood pressure and provide cardiovascular and renal protection. Ramipril is a prodrug: after absorption, the liver converts it to ramiprilat, the active form that produces the therapeutic effect.

Ramipril is licensed in the UK for the following indications: treatment of hypertension; treatment of symptomatic heart failure; prevention of cardiovascular events (heart attack and stroke) in patients at high cardiovascular risk, based on evidence from the HOPE trial; treatment of diabetic nephropathy in patients with type 2 diabetes who have early kidney disease indicated by microalbuminuria; and treatment of non-diabetic nephropathy where proteinuria is 3 g or more per day. The four available strengths allow careful dose titration across all these indications.

Ramipril is available as a generic medicine from multiple manufacturers and is one of the most commonly prescribed ACE inhibitors in UK primary care. It features prominently in NICE guideline NG136 (hypertension) and NICE guideline NG106 (heart failure) as a recommended medicine in each condition.

Ramipril lowers blood pressure and provides cardiovascular and renal protection through its action on the renin-angiotensin system.

The Renin-Angiotensin System

The renin-angiotensin system is a hormonal pathway that plays a central role in BP regulation. The kidneys release renin, which triggers a cascade leading to the production of angiotensin II. Angiotensin II causes blood vessels to narrow and the body to retain sodium and water, both of which raise blood pressure. Sustained angiotensin II activity also contributes to structural damage in the heart, blood vessels, and kidneys over time.

ACE Inhibition by Ramiprilat

Ramiprilat blocks the ACE enzyme, preventing the conversion of angiotensin I to angiotensin II. Without angiotensin II, blood vessels remain relaxed and widened, sodium retention is reduced, and blood pressure falls. Ramiprilat also reduces the breakdown of bradykinin, which contributes further to vasodilation. This bradykinin effect is also responsible for the dry cough associated with ACE inhibitors.

In heart failure, reducing vascular resistance and circulating volume with an ACE inhibitor reduces the mechanical workload on the heart, improving symptoms and long-term outcomes. In high cardiovascular risk patients, ramipril reduces the likelihood of cardiovascular events through improved endothelial function and reduced arterial stiffness, independently of its blood pressure-lowering effect. In diabetic and non-diabetic nephropathy, lowering the pressure inside kidney filtering units slows the rate of disease progression.

Always take ramipril exactly as your prescriber instructs. The information below summarises key points from the current UK SmPC. Read the Patient Information Leaflet supplied with your medicine before starting treatment.

• Take ramipril once daily. For most indications, the dose is taken once in the morning. Some prescribers may advise splitting the dose into two smaller doses taken morning and evening for certain indications. Follow your prescriber's specific instructions.
• Ramipril can be taken with or without food.
• Swallow the tablet whole or dissolve it in water if swallowing is difficult. Some ramipril tablet formulations can be dissolved or dispersed in a small amount of water. Check the Patient Information Leaflet for your specific product.
• If you miss a dose, take it as soon as you remember on the same day. If you only remember the following day, skip the missed dose and continue as normal. Do not take two doses on the same day.
• Do not stop taking ramipril without speaking to your prescriber first. High blood pressure, heart failure, and cardiovascular risk all require ongoing management.
• Your prescriber will typically start you at a low dose and increase it gradually over several weeks, monitoring your blood pressure, kidney function, and potassium levels. Attend all follow up appointments so your response to treatment can be safely assessed and your dose optimised.

Ramipril tablets are available in four strengths, supporting careful dose titration across all licensed indications.

Ramipril 1.25 mg Tablets

The 1.25 mg tablet is the lowest available strength. It is used as a cautious starting dose in patients at high risk of a significant first dose blood pressure drop, including those with heart failure, patients who are volume depleted or on diuretics, and older patients who may be more sensitive to the initial blood pressure lowering effect. Starting at 1.25 mg allows the prescriber to assess tolerability before any increase.

Ramipril 2.5 mg Tablets

The 2.5 mg tablet is a standard starting dose for hypertension in many patients and is also used in the titration schedules for heart failure and cardiovascular risk reduction. Blood pressure is typically reviewed after three to four weeks, with a possible increase to 5 mg if further blood pressure control is needed.

Ramipril 5 mg Tablets

The 5 mg tablet is a common maintenance dose for hypertension. Many patients achieve adequate blood pressure control at 5 mg once daily. It is also a key dose in the HOPE trial evidence for cardiovascular risk reduction, which demonstrated benefit at 10 mg once daily, making 5 mg the midpoint dose in the titration towards the target. For heart failure, 5 mg is within the standard dose range.

Ramipril 10 mg Tablets

The 10 mg tablet is the maximum recommended dose for most indications and is the target maintenance dose in the cardiovascular risk reduction indication based on the HOPE trial protocol. For hypertension, if 5 mg does not provide adequate blood pressure control, the dose may be increased to 10 mg once daily. All dose adjustments are made by your prescriber. Do not change your dose without medical advice.

Like all medicines, ramipril can cause side effects. The information below is based on the current UK SmPC. Refer to the Patient Information Leaflet for the full list.

Common Side Effects (may affect up to 1 in 10 people)

• Dry, persistent cough. This is the most common side effect of ramipril and all ACE inhibitors. It results from bradykinin accumulation and can develop at any time during treatment. If troublesome, speak to your prescriber about switching to an ARB such as losartan, which does not cause this effect.
• Dizziness or lightheadedness, particularly on standing. More likely at the start of treatment or after a dose increase.
• Headache
• Fatigue

Uncommon Side Effects (may affect up to 1 in 100 people)

• Nausea, vomiting, or diarrhoea
• Raised blood potassium (hyperkalaemia)
• Changes in kidney function, particularly in patients with pre existing kidney disease or reduced kidney blood supply
• Skin rash

Serious Side Effects: Seek Urgent Medical Attention

Go to your nearest accident and emergency department or call 999 immediately if you experience:

• Angioedema: sudden swelling of the face, lips, tongue, or throat. This is rare but potentially life threatening and is a class effect of all ACE inhibitors. Throat swelling can obstruct breathing. Seek emergency help immediately. If you have had angioedema from any ACE inhibitor before, do not take ramipril.
• Signs of severely raised potassium such as muscle weakness, irregular heartbeat, or confusion
• A marked reduction in urine output, which may indicate acute kidney injury

Report any suspected side effect to your prescriber, pharmacist, or via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Ramipril Tablets May Be Suitable If You:

• Are an adult with a confirmed diagnosis of hypertension
• Have symptomatic heart failure
• Have established cardiovascular disease or are at high cardiovascular risk and your prescriber has assessed that cardiovascular risk reduction with an ACE inhibitor is appropriate
• Have type 2 diabetes with microalbuminuria or non-diabetic nephropathy with significant proteinuria
• Are already prescribed ramipril and require a repeat prescription through an online prescribing service

Ramipril Tablets Are Not Suitable If You:

• Are pregnant or planning to become pregnant. Ramipril is contraindicated in pregnancy. ACE inhibitors cause serious harm to the developing baby, particularly in the second and third trimesters, including kidney damage and foetal death. Contact your prescriber immediately if you become pregnant while taking ramipril.
• Are breastfeeding
• Have a history of angioedema related to previous ACE inhibitor treatment, or hereditary or idiopathic angioedema
• Have severe kidney impairment or are on dialysis
• Are taking aliskiren and have diabetes or moderate to severe kidney impairment
• Have a known allergy or hypersensitivity to ramipril, any other ACE inhibitor, or any excipient listed in the SmPC
• Are under 18 years of age

Tell your prescriber about all medicines you take. The following interactions are of particular clinical importance for ramipril:

• Potassium supplements, potassium-sparing diuretics (such as spironolactone or amiloride), and potassium-containing salt substitutes: these can raise blood potassium to dangerous levels when combined with ramipril.
• NSAIDs such as ibuprofen: regular use can reduce the blood pressure lowering effect of ramipril and increase the risk of kidney problems.
• Lithium: ramipril can increase lithium blood levels. Close monitoring is required.
• Diuretics: combining ramipril with a diuretic increases the risk of a first dose blood pressure drop. Your prescriber will manage this carefully.
• Aliskiren: contraindicated in combination with ramipril in patients with diabetes or significant kidney impairment.
• Antidiabetic medicines including insulin: ACE inhibitors may enhance the blood glucose lowering effect. Patients with diabetes should monitor blood glucose carefully when starting ramipril.

Your prescriber will review all current medicines during the clinical assessment before any prescription is considered.

Ramipril is a Prescription Only Medicine. The clinical consultation is the essential first step. A prescription will only be issued if a registered prescriber concludes, based on their individual assessment of your circumstances, that ramipril is clinically appropriate for you.

During your online consultation with Pharmacy Planet, a registered prescriber will review the information you provide. This includes your diagnosis, blood pressure history, cardiac history, kidney function where available, current medicines, and other relevant medical information. The prescriber will assess which indication applies, which strength is appropriate, and whether online prescribing is suitable for your situation.

Not all consultations will result in a prescription. The prescriber may request recent blood test results or recommend a different medicine. Heart failure, post-MI care, and nephropathy management often involve specialist oversight that may not be appropriate for online prescribing initiation. This process is designed to protect your safety.

If you are under the care of your GP, cardiologist, or nephrologist, please keep them informed of all medicines prescribed through online services. Coordinated care supports the safest approach to BP regulation, heart health, and cardiovascular therapy.

• Store below 25°C.
• Store in the original packaging to protect from moisture and light.
• Keep out of the sight and reach of children.
• Do not use after the expiry date printed on the packaging.
• Do not dispose of medicines via household waste or wastewater. Return unused or out of date tablets to your pharmacist for safe disposal.
• Full storage instructions are provided in the Patient Information Leaflet supplied with your medicine.

The table below compares commonly prescribed ACE inhibitor tablets and capsules available at Pharmacy Planet. All are prescription-only medicines that act on the renin-angiotensin system to lower blood pressure.

Important: This comparison is for general information only and does not replace medical advice. A prescriber will decide which treatment is suitable for you following an online consultation.

Pharmacy Planet is a GPhC-registered online pharmacy providing access to prescription medicines through a clinically led consultation process. Our registered prescribers and pharmacists are committed to patient safety, clinical accuracy, and responsible prescribing.

We follow GPhC standards, MHRA guidance, and ASA advertising regulations in all aspects of our service. Every prescription is reviewed and dispensed by qualified healthcare professionals. We provide clear, factual information to help patients understand their antihypertensive medication and make informed decisions about their BP regulation and cardiovascular therapy.

If you have questions about ramipril, heart health, or any other medicine, our pharmacy team is available to help. We are committed to transparent, patient centred care.

References

1. Electronic Medicines Compendium (eMC). Ramipril 1.25 mg, 2.5 mg, 5 mg and 10 mg tablets — Summary of Product Characteristics. https://www.medicines.org.uk/emc. Accessed May 2026.
2. National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE guideline NG136. https://www.nice.org.uk/guidance/ng136. Accessed May 2026.
3. National Institute for Health and Care Excellence (NICE). Chronic heart failure in adults: diagnosis and management. NICE guideline NG106. https://www.nice.org.uk/guidance/ng106. Accessed May 2026.
4. NHS. Ramipril. https://www.nhs.uk/medicines/ramipril. Accessed May 2026.
5. Joint Formulary Committee. British National Formulary (BNF). Ramipril. BMJ Group and Pharmaceutical Press. https://bnf.nice.org.uk. Accessed May 2026.
6. Medicines and Healthcare products Regulatory Agency (MHRA). Yellow Card — report a side effect. https://yellowcard.mhra.gov.uk. Accessed May 2026.